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Background. Belinostat is a novel histone deacetylase inhibitor. Primary Objectives. Maximum tolerated dose (MTD) and dose
limiting toxicities (DLTs) of belinostat (Bel) in combination with doxorubicin (Dox) in solid tumours (phase I) and response rate
(RR) in soft tissue sarcomas (phase II).Methods. Bel was administered as a 30-minute IV infusion on days 1–5 and on day 5withDox.
The dose escalation schedule was as follows: cohort 1: Bel 600mg/m2 and 50mg/m2 Dox, cohort 2: Bel 600mg/m2 and 75mg/m2
Dox, cohort 3: Bel 800mg/m2 and 75mg/m2 Dox, and cohort 4: Bel 1000mg/m2 and 75mg/m2 Dox. Results. 41 patients were
included (25 in phase I, 16 in phase II). Adverse events were fatigue (95%), nausea (76%), and alopecia (63%). There was one DLT,
grade 3 rash/hand and foot syndrome. MTD was Bel 1000mg/m2/d and Dox 75mg/m2. Four responses were seen: 2 PR in phase
I, RR of 8%; in phase II, 1 PR/1 CR, RR of 13%, and 9 patients (56%) with SD. Conclusion. The combination was well tolerated.
Response rate was moderate but median time to progression was 6.0 months (95% CI, 1.6–9.7 months) which is superior to some
reports of single-agent Dox.
1. Introduction
Soft tissue sarcomas (STS) are rare tumours with an annual
incidence of 2-3/100,000. Overall STS account for approxi-
mately 1% of all malignancies.Themedian overall survival for
patients with metastatic disease is approximately 12 months
[1]. There are more than 100 different histological subtypes of
STS according to the WHO 2013 classification [2].
Standard curative treatment for high grade STS is wide
surgical excision and adjuvant radiotherapy. Neoadjuvant
and/or adjuvant chemotherapy can also be considered in
selected cases [3]. In rare cases, surgery including amputation
is necessary. The primary metastatic site is the lung; however
metastases to the bone, liver, and other organs, depending on
the site of origin and subtype, are also seen. Chemotherapy is
widely used in the treatment of metastatic disease but is
mainly palliative [4]. The majority of initial chemosensitive
patients develop resistance. Doxorubicin appears to be the
most active drug in the treatment of STS with a cumulative
response rate in treatment naive patients of approximately
20–30% [5]. The reported response rate for doxorubicin in
combination with ifosfamide ranges between 50 and 60%
[6], though this combination has not demonstrated improved
survival. Other possible treatment options are trabectedin,
pazopanib, and paclitaxel in angiosarcoma [7] and a combi-
nation of gemcitabine and docetaxel in leiomyosarcoma and
undifferentiated pleomorphic sarcoma.
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PXD101, currently known as belinostat, is developed by
Spectrum Pharmaceuticals and Onxeo (former Topotarget)
and belongs to a new class of hydroxamate-type histone
deacetylase (HDAC) inhibitors. HDAC inhibitors are induc-
ers of transformed cell differentiation, cell cycle arrest, and
apoptosis. They exert their targeted action during post-
translational acetylation of core nucleosomal histones, which
affects chromatin structure and leads to the expression of
genes associated with cell cycle arrest and tumour suppres-
sion.The effects of HDACs are not limited to histone deacety-
lation. HDACs also act as members of a protein complex
to recruit transcription factors to promotor region of genes,
including those of tumour suppressors, and they affect the
acetylation status of specific cell cycle regulatory proteins [8].
Previous published data with belinostat in vitro cancer
models have demonstrated a potent antiproliferative and
HDAC inhibitory activity and inhibition proliferation of a
large variety of human cancer cell lines. In vivo, belinostat
inhibits growth in human tumour xenografts without appar-
ent toxicity to the host mice [9].
Several other preclinical efficacy models using belinostat
alone or in combination with well-established cancer ther-
apeutics have demonstrated tumour growth inhibition and
dose dependent increase in animal survival. A strong syn-
ergistic effect was obtained in the combination of belinostat
and doxorubicin in the sarcoma cell lines SaOS2 and U2OS
(Synergistic In Vitro Growth-Inhibitory Activity of Belinos-
tat/Doxorubicin on Human Sarcoma Cell Lines, nonpublished
data).
Doxorubicin is a widely used anthracycline which acts
as a topoisomerase II inhibitor and intercalates into double-
strandedDNA and produces structural changes that interfere
with DNA and RNA synthesis. DNA-damaging free radical
formation may also be important. In soft tissue sarcoma,
single-agent doxorubicin 60 to 75mg/m2 is recommended.
Data from previous phase I trials, using belinostat as
monotherapy, has established a maximum tolerated dose
(MTD) of 1000mg/m2/d for 5 consecutive days repeated in a
3-week schedule for patients with solid tumours and haema-
tological neoplasms. Antitumour effects were observed in a
number of different neoplasms, among them 2 STS patients
who had prolonged stable disease (SD) for 7 and 14 months,
respectively [10, 11].
These data led to the initiation of this trial: a dose
escalation phase I/II study of belinostat combined with dox-
orubicin in patients with solid tumours including an MTD
expansion phase II part of belinostat combined with doxoru-
bicin in patients with advanced STS.This study was based on
the hypothesis that the addition of belinostat to doxorubicin
would improve the antitumour effect, without significantly
increasing toxicity.
The primary objectives of this trial were to determine the
MTD, DLTs, and the efficacy of the belinostat/doxorubicin
combination treatment. The secondary objectives were to
examine the time to response, duration of response, and sur-
vival following treatment with belinostat/doxorubicin, dis-
ease control rate (complete response (CR), partial response
(PR), and stable disease (SD)), and pharmacokinetics (PK).
2. Materials and Methods
This study was an open-label multicentre, dose escalation
phase I/II study (ClinicalTrials.gov: NCT00878800). It was
conducted at 3 sites (AarhusUniversityHospital, Department
of Oncology, Denmark; Royal Marsden Hospital, NHS Trust,
Sutton, Surrey, UK; and Herlev Hospital, Department of
Oncology, Denmark). The trial was conducted in accordance
with the Declaration of Helsinki and ICH-GCP. It was
approved by local regulatory authorities and by independent
ethics committees, EudraCT number 2006-004345-42. All
participating patients provided written informed consent
before any study procedures were performed.
2.1. Eligibility Criteria. Eligibility criteria were as follows:
patients 18 years or older and giving informed consent;
performance status (ECOG) ≤2; life expectancy of at least
3 months; acceptable liver, renal, coagulation, and bone
marrow function; serumpotassiumwithin normal range; and
acceptable coagulation status. Eligibility criteria for dose
escalation phase I part: patients with histological or cytolog-
ical confirmed solid tumours (including sarcomas), with no
known curative therapy. Eligibility criteria for MTD expan-
sion phase II part: patients with an established diagnosis of
STS in need of first-line chemotherapy and with measurable
disease.
2.2. Main Exclusion Criteria. Main exclusion criteria were
investigational treatment within 4 weeks prior to study
treatment; prior anticancer therapy within the last 3 weeks;
coexisting significant medical condition or active infection;
concurrent second malignancy; history of hypersensitivity
to doxorubicin; pregnancy. Main exclusion criteria for dose
escalation phase I part: more than two prior doses of
anthracycline ormore than three prior lines of chemotherapy
given for metastatic disease. Main exclusion criteria forMTD
expansion phase II part: prior chemotherapy and LVEF below
normal range (45% by MUGA).
2.3. Study Design. Belinostat was administered as a 30-
minute intravenous infusion every 24 hours on days 1–5 and
on day 5 in combinationwith doxorubicin, in a 3-week sched-
ule, and doxorubicin was given after belinostat. The dose
escalation schedule was as follows: belinostat 600mg/m2 and
50mg/m2 doxorubicin (cohort 1), 600mg/m2 and 75mg/m2
doxorubicin (cohort 2), 800mg/m2 and 75mg/m2 doxoru-
bicin (cohort 3), and 1000mg/m2 and 75mg/m2 doxorubicin
(cohort 4). See Table 1 for the dose escalation schedule.
Completion of 6 cycles of belinostat/doxorubicin was
considered the standard trial duration for each patient.
Patients who achieved clinical benefit from the treatment
(objective response or stable disease) could continue belino-
stat treatment beyond cycle 6. If the maximum cumulative
dose of doxorubicin 450mg/m2 was reached, the treatment
would continue with belinostat as monotherapy. In the phase
I part, at least 3 patients were treated at each dose level. If a
DLT was found in one of 3 patients, the cohort was expanded
to a total of 6 patients.When theMTDwas established, a total
of 20 patients with STS were to be enrolled in the phase II
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Table 1: Dose escalation scheme for the combination treatment with belinostat and doxorubicin.
Phase Purpose Eligibility Cohort Bel (mg/m2) Dox (mg/m2) 𝑁
I Dose escalation pts with STS and other solid tumours
1 600 50 3
2 600 75 7
3 800 75 9
4 1000 75 6
II MTD expansion pts with STS only Expansion 1 MTD MTD 20 (16 plus 4 from cohort 4)
Expansion 2 MTD MTD 0
STS: soft tissue sarcoma.
MTD: maximum tolerated dose.
part of the study at the MTD dose level to examine efficacy
and safety in this specific patient population. The phase II
part of the trial would be stopped if nomore than 2 responses
were seen among the 20 patients within their first 2 treatment
cycles.
2.4. Safety and Tolerability. Patients had medical history,
concomitant medication, physical exam, performance sta-
tus, vital signs, electrocardiogram (ECG), haematology and
chemistry profiling, urine analysis, chest X-ray, and tumour
evaluation, investigated at baseline. MUGA scan and tro-
ponin levels were performed at baseline, at day 1 of every
2nd cycle, and at the end of treatment. Safety assessments
including blood test and clinical assessments were performed
on days 1, 2, 3, 4, 5, 8, and 15 during cycles 1 and 2 and weekly
from cycle 3 onwards and every second week for a minimum
of 4 weeks after the end of treatment.
In cycles 1 and 2, ECG was performed before treatment
and within 1 h after treatment with each administration
instance of belinostat and doxorubicin. In cycles 3–6 one
ECG was performed before treatment and within 1 h after
treatment with the belinostat administration.
Adverse events were graded using the NCI common ter-
minology criteria for adverse events (NCI-CTCAE) version
3.0. A DLT was defined as the presence of one of the fol-
lowing toxicities during the first cycle of treatment: absolute
neutrophil count <0.5 ∗ 109/L lasting for ≥7 days; absolute
neutrophil count<0.5∗ 109/Lwith fever>39∘C; platelet count
<25 ∗ 109/L; and any other drug-related grade 3 or 4
nonhaematological toxicity (with the exception of alopecia,
brief nausea and vomiting, diarrhoea, rash, arthralgia, and
myalgia). If, despite optimal treatment, grade 3 nausea and/or
vomiting persisted or if grade 4 diarrhoea in spite of standard
therapeutic measures persisted or there was inability to toler-
ate a full 5-day dosing cycle due to toxicity or any drug-related
adverse events resulting in more than a 14-day treatment
delay, these were included in the DLT definition.
2.5. Pharmacokinetic Analyses. The following PK parameters
were determined: elimination half-life (𝑡
1/2
), maximum con-
centration (𝐶max), time to maximum concentration (𝑡max),
area under the curve (AUC
0−𝑡last
and AUC
∞
), elimination
rate constant (𝜆𝑧), and volume of distribution (𝑉c and 𝑉ss).
Blood sampling for belinostat alone was performed on cycle
1 day 4 (before treatment and 0min, 5min, 15min, 30min,
1 h, 2 h, 2 h 15min, 2 h 30min, 3 h, 4 h, 6 h, 8 h, and 24 h after
treatment). Blood sampling for belinostat/doxorubicin was
performed on cycle 1 day 5 (before treatment and 0min,
5min, 15min, 30min, 1 h, 2 h, 2 h 15min, 2 h 30min, 3 h, 4 h,
6 h, 8 h, and 24 h after treatment).
2.6. Tumour Response. Patients were evaluated clinically after
each treatment cycle and radiologically at baseline and after
every two cycleswith computed tomography (CT) until PD.A
confirmatory scanwas obtained 4weeks following initial doc-
umentation of an objective response (CR and PR). Response
and progression were evaluated according to the Response
Evaluation Criteria in Solid Tumours (RECIST, version 1.0)
[12]. Relevant tumourmarkers such as CA125, CEA, and PSA
were used to assess the effect of belinostat/doxorubicin on the
various tumour types.
2.7. Statistics. Descriptive statistics (incidence and confi-
dence intervals) were used to summarize the number of
patients exhibiting objective response (OR) or stable disease
(SD). Data are expressed as a proportion + 95% confidence
interval.
3. Results
A total of 25 patients were enrolled and treated in the dose
escalation phase I part of the study and a total of 16 patients
were enrolled and treated in the MTD expansion phase II
part. Four patients with STS in cohort 4 were treated at the
MTD dose level and therefore these patients were included
in the MTD phase II part. See Table 2 for demographics.
The patients received a median of 4 cycles (range 1–19)
of belinostat and 4 cycles (range 1–9) of doxorubicin and 6
patients continued with single-agent belinostat.
3.1. Dose Limiting Toxicities andMaximumToleratedDose. In
the dose escalation phase I part, one event of CTC grade 3
rash/hand and foot syndrome, in cohort 3, day 22, was con-
sidered as aDLT; the patient had progressive disease andwent
off the study after day 2 of cycle 2.
TheMTDwas established at the highest tested dose level:
belinostat 1000mg/m2/d and doxorubicin 75mg/m2 (cohort
4).
3.2. Safety, Tolerability, and Dose Reduction. A total of 1059
treatment emergent adverse events were recorded in the
study; 63% of these adverse events (AE) were assessed as
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Table 2: Demographics.
Characteristics Patients
Total number of patients 41
Age (years)
Mean 57.1
Range (30–71)
Gender
Female 15 (37%)
Male 26 (63%)
ECOG performance status 𝑁: 41
0 23
1 14
2 4
Tumour type DE (𝑁: 25) MTD (𝑁: 16)
Solid tumours, total 15 0
Colorectal adenocarcinoma 1 0
Non-small cell lung cancer 1 0
Renal pelvis carcinosarcoma 1 0
Pancreas adenocarcinoma 1 0
Cholangiocarcinoma 1 0
Cervix cell carcinoma 1 0
Stromal tumour of unknown 1 0
Anal planocellular carcinoma 1 0
Ocular malignant melanoma 3 0
Bladder carcinoma 1 0
Renal carcinoma 1 0
Squamous cell carcinoma 1 0
Thyroid carcinoma 1 0
Sarcomas, total 10 16
Liposarcoma 2 3
Leiomyosarcoma 2 5
Chondrosarcoma 1 3
Angiosarcoma 1 1
Myxofibrosarcoma 1 1
Undif pleomorphic sarcoma 1 1
Rhabdomyosarcoma 1 0
Fibrosarcoma 1 0
Myogenic sarcoma 0 1
Synovial sarcoma 0 1
DE: dose escalation phase I study.
MTD: maximum tolerated dose phase II study.
related to study drugs. The most frequent AEs across all dos-
ing groups were fatigue (95%), nausea (76%), alopecia (63%),
vomiting (59%), constipation (54%), neutropenia (54%),
dyspnoea (54%), decreased appetite (54%), headache (44%),
and injection site reaction (39%). See Table 3 for related CTC
grade 3 and 4 adverse events.
The most frequent AEs occurring in the MTD expansion
phase II part were fatigue (94%), nausea (88%), and alopecia
(81%).
Three AEs in 2 patients led to study discontinuation:
febrile neutropenia (grade 4) and fatigue (grade 3) both
recorded in 1 patient and an episode of neutropenic sepsis
(grade 4) recorded in another patient. Both patients were
treated at the 800mg belinostat and 75mg doxorubicin
dosing level.
A total of 34 SAEs in 23 patients were recorded. One
patient died of disease progression, unrelated to study drug.
Six SAEs in 6 patients were CTC grade 4, 18 SAEs in 14
patientswereCTCgrade 3, and 9 SAEs in 8 patientswereCTC
grade 2. The 6 grade 4 SAEs were all considered treatment
related and were febrile neutropenia (3 pts (1 patient cohort 2
day 17, 1 patient cohort 3 day 15, and 1 patientMTD cohort day
37)), neutropenia (2 patients, both patients MTD cohort day
15 and day 148), and neutropenic sepsis (1 patient cohort 3 day
15).
Of the 20 patients with sarcomas treated at theMTDdose,
12 patients (60%) experienced CTC grade 4 neutropenia. A
total of 11 patients (55%) required a dose reduction of both
belinostat and doxorubicin and 2 of doxorubicin only. Two
patients discontinued treatment after completing cycle 1 due
to progressive disease.
3.3. Pharmacokinetics. Following a 30-minute IV infusion
of belinostat at 600, 800, and 1000mg/m2 on day 4 and
coadministration with 50 or 75mg/m2 doxorubicin on day 5,
plasma concentrations of belinostat declined in an apparent
multiphasic manner, with a rapid distribution/elimination
phase followed by a longer terminal elimination phase. The
geometricmean apparent elimination half-life (𝑡
1/2
) appeared
dose independent ranging from approximately 1.9 to 4.8
hours with belinostat plasma concentrations generally quan-
tifiable up to 8–24 hours after the start of the infusion. See
Table 4 for pharmacokinetics.
Regarding the in-between-patient variability (16.2 to
43.2% for AUC
0−𝑡last
and 13.6 to 69.2% for 𝐶max) belinos-
tat appeared to exhibit dose-proportional pharmacokinetics
across the dose range studied. In addition, there was no evi-
dence that coadministration of doxorubicin had any effect on
belinostat exposure.
The metabolite doxorubicinol was steadily formed from
parent drug with median 𝑡max ranging from 2.0 to 4.9 hours
after start of doxorubicin infusion compared to median
𝑡max of 0.24 to 0.5 hours for doxorubicin. The exposure of
doxorubicin and its metabolite doxorubicinol showed dose-
proportional increase between the 50 and 75 mg/m2 doxoru-
bicin dose levels when coadministered with 600, 800, and
1000mg/m2 belinostat on day 5. The geometric mean 𝑡
1/2
of
doxorubicin was similar for all doses ranging from 7.6 to 10.8
hours.
Dose normalised AUC
0−𝑡last
and 𝐶max appeared relatively
consistent across treatment groups on both days 4 and 5 indi-
cating that doxorubicin exhibited linear pharmacokinetics
results between 50 and 75mg/m2 doses; coadministration of
belinostat had no effect on doxorubicin exposure.
3.4. Tumour Response and Survival Analysis. See Figures 2, 3,
and 4.
Dose escalation phase I part (𝑛 = 25): two patients
(one with the diagnosis of squamous cell carcinoma of
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Table 3: Grade 3 and 4 treatment-related adverse events occurring in both the DE and MTD part of the study.
Adverse event,𝑁 (%)
Cohort 1 (𝑁: 3)
Belinostat
600 (mg/m2)
Doxorubicin
50 (mg/m2)
Cohort 2 (𝑁: 7)
Belinostat
600 (mg/m2)
Doxorubicin
75 (mg/m2)
Cohort 3 (𝑁: 9)
Belinostat
800 (mg/m2)
Doxorubicin
75 (mg/m2)
Cohort 4 (𝑁: 6)
Belinostat
1000 (mg/m2)
Doxorubicin
75 (mg/m2)
MTD (𝑁: 16)
Belinostat
1000 (mg/m2)
Doxorubicin
75 (mg/m2)
Fatigue
Grade 3 0 (0%) 0 (0%) 2 (22%) 0 (0%) 3 (19%)
Grade 4 0 (0%) 0 (0%) 1 (11%) 0 (0%) 0 (0%)
Neutropenia
Grade 3 0 (0%) 3 (43%) 2 (22%) 1 (17%) 4 (25%)
Grade 4 0 (0%) 3 (43%) 0 (0%) 1 (17%) 5 (31%)
Anaemia
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (13%)
Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Febrile neutropenia
Grade 3 0 (0%) 1 (14%) 0 (0%) 0 (0%) 2 (13%)
Grade 4 0 (0%) 1 (14%) 1 (11%) 0 (0%) 1 (6%)
Mucosal inflam
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (6%)
Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Abdominal abscess
Grade 3 0 (0%) 1 (14%) 0 (0%) 0 (0%) 0 (0%)
Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Bacteraemia
Grade 3 0 (0%) 1 (14%) 0 (0%) 0 (0%) 0 (0%)
Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Prolonged QT
Grade 3 0 (0%) 1 (14%) 0 (0%) 0 (0%) 0 (0%)
Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Neutrophil count
Grade 3 0 (0%) 1 (14%) 0 (0%) 3 (50%) 0 (0%)
Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Decreased appetite
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (6%)
Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Rash
Grade 3 0 (0%) 0 (0%) 1 (11%) 0 (0%) 0 (0%)
Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Neutropenic sepsis
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Grade 4 0 (0%) 0 (0%) 1 (11%) 0 (0%) 0 (0%)
Hypersensitivity
Grade 3 0 (0%) 0 (0%) 1 (11%) 0 (0%) 0 (0%)
Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Headache
Grade 3 0 (0%) 0 (0%) 1 (11%) 0 (0%) 0 (0%)
Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Leukopenia
Grade 3 0 (0%) 0 (0%) 0 (0%) 1 (17%) 0 (0%)
Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
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Table 3: Continued.
Adverse event,𝑁 (%)
Cohort 1 (𝑁: 3)
Belinostat
600 (mg/m2)
Doxorubicin
50 (mg/m2)
Cohort 2 (𝑁: 7)
Belinostat
600 (mg/m2)
Doxorubicin
75 (mg/m2)
Cohort 3 (𝑁: 9)
Belinostat
800 (mg/m2)
Doxorubicin
75 (mg/m2)
Cohort 4 (𝑁: 6)
Belinostat
1000 (mg/m2)
Doxorubicin
75 (mg/m2)
MTD (𝑁: 16)
Belinostat
1000 (mg/m2)
Doxorubicin
75 (mg/m2)
Pneumonia
Grade 3 0 (0%) 0 (0%) 0 (0%) 1 (17%) 0 (0%)
Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Wound infection
Grade 3 0 (0%) 0 (0%) 0 (0%) 1 (17%) 0 (0%)
Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Neutrophil count decreased
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Grade 4 0 (0%) 0 (0%) 0 (0%) 1 (17%) 3 (19%)
Platelet count decreased
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Grade 4 0 (0%) 0 (0%) 0 (0%) 1 (17%) 0 (0%)
Blood sodium decreased
Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (6%)
Diarrhoea
Grade 3 0 (0%) 1 (14%) 0 (0%) 0 (0%) 0 (0%)
Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
DE: dose escalation phase I study.
MTD: maximum tolerated dose phase II study.
Table 4: Pharmacokinetic parameters of belinostat (Bel) following administration of Bel alone (cycle 1 day 4) or in combination with
doxorubicin (cycle 1 day 5).
Occasion
600mg/m2 Bel + 50mg/m2
doxorubicin
600mg/m2 Bel + 75mg/m2
doxorubicin
800mg/m2 Bel + 75mg/m2
doxorubicin
1000mg/m2 Bel +
75mg/m2 doxorubicin
Day 4 Day 5 Day 4 Day 5 Day 4 Day 5 Day 4 Day 5
(𝑁 = 3) (𝑁 = 3) (𝑁 = 7) (𝑁 = 6) (𝑁 = 8) (𝑁 = 6) (𝑁 = 21) (𝑁 = 19)
AUC
0–𝑡last (ng⋅h/mL) 10900 (16.2) 10400 (22.3) 9670 (40.0) 10400 (24.7) 12200 (28.5) 14600 (26.0) 23100 (35.4) 22100 (43.2)
𝐶max (ng/mL) 21100 (13.6) 18300 (36.2) 16800 (69.2) 17400 (45.1) 21400 (44.9) 26400 (30.0) 41100 (35.0) 37000 (59.1)
𝑡max
a (h) 0.533(0.500–0.550)
0.567
(0.550–0.583)
0.567
(0.500–0.783)
0.517
(0.467–0.667)
0.533
(0.500–0.583)
0.533
(0.483–0.583)
0.617
(0.500–0.750)
0.633
(0.517–1.60)
𝑡last
a (h) 24.5(22.4–24.6)
17.0
(17.0–20.1)
24.0
(8.55–24.5)
24.5
(16.2–24.7)
23.7
(8.47–24.6)
15.1
(8.50–24.6)
8.65
(1.05–24.0)
8.72
(8.50–24.7)
AUC
0–𝑡last (norm) 18.2 (16.2) 17.3 (22.3) 16.1 (40.0) 17.3 (24.7) 15.3 (28.5) 18.2 (26.0) 23.1 (35.4) 22.1 (43.2)
𝐶max (norm) 35.2 (13.6) 30.5 (36.2) 28.0 (69.2) 28.9 (45.1) 26.8 (44.9) 32.9 (30.0) 41.1 (35.0) 37.0 (59.1)
𝑡
1/2
(h) NC (NC) 2.53e (NC) 3.77b (136.4) 4.83b (45.7) 1.91c (129.8) 2.14c (114.9) 1.48d (71.3) 2.13 (119.4)
CL (L/h) NC (NC) 106e (NC) 129b (61.8) 111b (12.1) 127c (40.5) 91.0c (18.1) 81.6d (39.9) 85.2 (41.0)
𝑉ss (L) NC (NC) 72.8e (NC) 149b (365.2) 90.8b (7.1) 107c (195.5) 58.3c (29.5) 51.0d (45.1) 57.6 (61.8)
𝑁: number of patients studied.
aMedian (min–max).
(norm): normalised for dose.
NC: not calculable.
b
𝑁: 3.
c
𝑁: 4.
d
𝑁: 18.
e
𝑁: 1; individual parameter presented.
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Baseline before treatment
A: 14.7mm
(a)
Cycle 6, day 145 of treatment
(b)
Figure 1: Imaging of patient with complete remission.
the cervix (belinostat: 600mg/m2/doxorubicin: 75mg/m2)
and one retroperitoneal angiosarcoma (belinostat: 1000mg/
m2/doxorubicin: 75mg/m2)) had PR as objective response,
corresponding to a response rate of 8% (95% CI, 1–26%);
time to progression for these patients was 9.6 and 7.9 months,
respectively. Median duration of response was 3.9 months.
SD was observed in 16 (64%) patients; 7 (28%) had PD.
Median time to progression was 3.7 months (95% CI, 3.0–5.6
months). 18 patients had disease control corresponding to a
disease control rate of 72% (95% CI, 51–88%).
MTD expansion phase II part (𝑛 = 16): two patients out
of 16 had an objective response (pleomorphic sarcoma (CR)
and leiomyosarcoma (PR)), leading to a response rate of 13%
(95% CI, 2–38%), and one of these responses occurred after
cycle 2. Median duration of response was 7.9 months. SD was
observed in 9 (56%) patients and 5 (31%) had PD. Median
time to progressionwas 6.0months (95%CI, 1.6–9.7months).
Eleven patients had disease control, corresponding to a
disease control rate of 69% (95% CI, 41–89%).
In the MTD expansion phase II part the patient who
experienced a complete response was a female, age 38, with
a diagnosis of leiomyosarcoma. She experienced a partial
response after 49 days and a complete response after 145 days
and had progressive disease after 19 treatment cycles, on day
345. Serial imaging for this patient is displayed in Figure 1.
The trial stopping rule defined that if no more than 2
responses were seen among the first 20 patients within the
first 2 treatment cycles, the studywould be stopped.With only
one patient experiencing an early response, the study was
stopped for accrual based on data from 4 sarcoma patients
in the dose escalation phase and 16 patients at theMTD level.
3.5. Reasons for Discontinuation. PD was the most frequent
reason for discontinuation (73%), 4 patients withdrew con-
sent, 3 patients discontinued due to AEs, 3 patients discontin-
ued for other reasons, and 1 patient died due to PDwhich was
evaluated as being unrelated to treatment by the investigator.
4. Discussion
HDAC inhibitors are a new class of anticancer agents and are
being evaluated for the treatment of a variety ofmalignancies.
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Figure 2: Time to progression for phase I and phase II.
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Figure 3: Time to response for phase I and phase II.
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Figure 4: Duration of response for phase I and phase II.
Soft tissue sarcoma is a heterogeneous group of tumours and
patients with metastatic disease have a poor outcome.There-
fore, there is an urgent medical need to develop new treat-
ment options for this particular group of patients.
As previously mentioned preclinical data have shown a
strong synergistic effect of combining belinostat and doxoru-
bicin in the sarcoma cell lines SaOS2 and U2OS and clinical
data from a phase I trial using belinostat as monotherapy
showed prolonged SD in two pts with STS for 7 and 14
months, respectively [10]. In contrast other studies have
shown that there is little benefit in using belinostat as
monotherapy and that it should preferably be used in com-
bination with other agents [13–15]. The recognized ability of
HDAC inhibitors to affect the expression of genes involved in
DNA-damage is thought to be the cause of the synergy with
cytotoxic agents that specifically determine DNA-damage,
such as doxorubicin, a topoisomerase II inhibitor [16, 17].
Currently doxorubicin is the most effective drug in the
treatment of metastatic STS.Therefore, these data indicated a
strong rationale for conducting a study combining belinostat
and doxorubicin.
Our study demonstrated that belinostat 1000mg/m2/d
in combination with doxorubicin 75mg/m2 can be safely
administered to patients with advanced solid tumours. The
combination was generally well tolerated with the most com-
mon AEs being fatigue, nausea, alopecia, vomiting, constipa-
tion, and neutropenia; however neutropenia (all grades) was
observed in 54% of the patients across the different dosing
levels and 55% of the patients in the MTD expansion phase
II part experienced a dose reduction due to adverse events.
Two patients experienced a partial response in the dose
escalation phase I part, whereas 2 patients in theMTD expan-
sion phase II part also experienced responses, one having
an impressive complete remission and one having partial
response. The activity of the combination of belinostat and
doxorubicin in soft tissue sarcoma in terms of response rate
was 13%, which is in line with already published data on
single-agent doxorubicin, where a response rate of 14% is
reported [6]; however a significant number of patients (55%)
treated at the MTD dose level experienced stable disease, of
whom 7 patients were treated for 6 or more cycles.
There is no standard treatment for advanced chondrosar-
comas. Based on the preclinical study with activity of belinos-
tat + doxorubicin in bone derived sarcomas combined with a
positive observation of stable disease for 4 courses in one
patient with chondroblastic chondrosarcoma in the dose
escalation phase I part, we accepted the 3 patients with chon-
drosarcomas for the phase II trial.The patients were therefore
included in the analysis. We did not observe any objective
response in these 3 patients; one patient had progression after
2 courses, one patient had stable disease and progression after
4 courses, and the last patient had stable disease for 8 courses
and then progression. Therefore this subgroup of patients
did not influence the overall moderate response rate much.
Certain aspects in the setup of this study and in study
patient characteristics warrant further mentioning as poten-
tial reasons for influencing the moderate response rate:
the use of G-CSFs was not permitted in the study where
neutropenia (all grades) was as mentioned above observed
in 54% of all patients. Eleven patients (55%) from the MTD
expansion phase 2 part had a dose reduction in both belinos-
tat and doxorubicin due to adverse events.Thedose reduction
in 55% of the patients could be a potential cause for the mod-
erate response. Neutropenia (all grades) has been reported
in 37% with single-agent doxorubicin which is less than in
our study; in that trial G-CSF was also allowed and could
influence the incidence of neutropenia [6].
Three of the 4 responders were diagnosed with STS and
all of these were treated at the highest dose level (belino-
stat: 1000mg/m2/doxorubicin: 75mg/m2). If calculating the
response rate in the group of patients with STS that received
the highest dose level, the response rate is 15% and if
excluding the chondrosarcomas, the response rate is 18%.
The study was as previously mentioned designed with a
stopping rule based on response rate. Recent soft tissue sar-
coma studies have used stopping rules based on progression-
free rate, acknowledging the benefit of disease stabilization in
this disease [1, 18, 19] and SD was observed in 11 (55%) with
STS treated at the MTD dose level.
5. Conclusions
Belinostat is approved in the USA for the treatment of
relapsed/refractory peripheral T-cell lymphoma (PTCL) and
although one must conclude that there was no clear evidence
of synergy between belinostat and doxorubicin in terms of
objective tumour shrinkage in soft tissue sarcomas, median
time to progression in this studywas 6months, which is supe-
rior to some reports of first-line single-agent doxorubicin in
soft tissue sarcoma [20, 21].
Disclosure
The abstract was presented at the Sarcoma Poster Discussion
Session, ASCO 2015.
Sarcoma 9
Competing Interests
Robin L. Jones has been an advisor for Immune Design,
Adaptimmune, Immodulon, Blueprint, Eisai, Pharmamar,
Daiichi Sankyo,Merck Serono, and Lily. Poul Knoblauch is an
Oncology Nurse Specialist, Onxeo DK. The other authors
declare that there are no competing interests regarding the
publication of this paper.
References
[1] S. Sleijfer, I. Ray-Coquard, Z. Papai et al., “Pazopanib, a
multikinase angiogenesis inhibitor, in patients with relapsed or
refractory advanced soft tissue sarcoma: a phase II study from
the European organisation for research and treatment of cancer-
soft tissue and bone sarcoma group (EORTC Study 62043),”
Journal of Clinical Oncology, vol. 27, no. 19, pp. 3126–3132, 2009.
[2] C. D. M. Fletcher, J. A. Bridge, P. C. W. Hogendoorn, and F.
Mertens, WHO Classification of Tumours of Soft Tissue and
Bone, IARC, Lyon, France, 2013.
[3] The ESMO/European Sarcoma Network Working Group, “Soft
tissue and visceral sarcomas: ESMO Clinical Practice Guide-
lines for diagnosis, treatment and follow-up,” Annals of Oncol-
ogy, vol. 25, supplement 3, pp. iii102–iii112, 2014.
[4] G. Blackledge, A. van Oosterom, H. Mouridsen et al., “Doxoru-
bicin in relapsed soft tissue sarcoma: justification of phase II
evaluation of new drugs in this disease: an EORTC Soft Tissue
and Bone Sarcoma Group study,” European Journal of Cancer
and Clinical Oncology, vol. 26, no. 2, pp. 139–141, 1990.
[5] A. I. Spira and D. S. Ettinger, “The use of chemotherapy in soft-
tissue sarcomas,”TheOncologist, vol. 7, no. 4, pp. 348–359, 2002.
[6] I. Judson, J. Verweij, H. Gelderblom et al., “Doxorubicin alone
versus intensified doxorubicin plus ifosfamide for first-line
treatment of advanced or metastatic soft-tissue sarcoma: a
randomised controlled phase 3 trial,”The Lancet Oncology, vol.
15, no. 4, pp. 415–423, 2014.
[7] I. Letsa, C. Benson, O. Al-Muderis, and I. Judson, “Angiosar-
coma of the face and scalp: effective systemic treatment in the
older patient,” Journal of Geriatric Oncology, vol. 5, no. 3, pp.
276–280, 2014.
[8] G.-J. Arts, E. Langemeijer, R. Tissingh et al., “Adenoviral vectors
expressing siRNAs for discovery and validation of gene func-
tion,” Genome Research, vol. 13, no. 10, pp. 2325–2332, 2003.
[9] J. A. Plumb, P.W. Finn, R. J. Williams et al., “Pharmacodynamic
response and inhibition of growth of human tumor xenografts
by the novel histone deacetylase inhibitor PXD101,” Molecular
Cancer Therapeutics, vol. 2, no. 8, pp. 721–728, 2003.
[10] N. L. Steele, J. A. Plumb, L. Vidal et al., “A phase 1 pharmacoki-
netic and pharmacodynamic study of the histone deacetylase
inhibitor belinostat in patients with advanced solid tumors,”
Clinical Cancer Research, vol. 14, no. 3, pp. 804–810, 2008.
[11] P. Gimsing, M. Hansen, L. M. Knudsen et al., “A phase I clinical
trial of the histone deacetylase inhibitor belinostat in patients
with advanced hematological neoplasia,” European Journal of
Haematology, vol. 81, no. 3, pp. 170–176, 2008.
[12] P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guide-
lines to evaluate the response to treatment in solid tumors,”
Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–
216, 2000.
[13] S. S. Ramalingam, C. P. Belani, C. Ruel et al., “Phase II study of
belinostat (PXD101), a histone deacetylase inhibitor, for second
line therapy of advanced malignant pleural mesothelioma,”
Journal of Thoracic Oncology, vol. 4, no. 1, pp. 97–101, 2009.
[14] A. Cashen,M. Juckett, A. Jumonville et al., “Phase II study of the
histone deacetylase inhibitor belinostat (PXD101) for the treat-
ment of myelodysplastic syndrome (MDS),”Annals of Hematol-
ogy, vol. 91, no. 1, pp. 33–38, 2012.
[15] A. Grassadonia, P. Cioffi, F. Simiele, L. Iezzi, M. Zilli, and C.
Natoli, “Role of hydroxamate-based histone deacetylase inhibi-
tors (Hb-HDACIs) in the treatment of solid malignancies,”
Cancers, vol. 5, no. 3, pp. 919–942, 2013.
[16] M. Stiborova´, T. Eckschlager, J. Poljakova´ et al., “The syner-
gistic effects of DNA-targeted chemotherapeutics and histone
deacetylase inhibitors as therapeutic strategies for cancer treat-
ment,” Current Medicinal Chemistry, vol. 19, no. 25, pp. 4218–
4238, 2012.
[17] A. R. Venkitaraman, “Modifying chromatin architecture during
the response toDNAbreakage,”Critical Reviews in Biochemistry
and Molecular Biology, vol. 45, no. 1, pp. 2–13, 2010.
[18] M. Van Glabbeke, J. Verweij, I. Judson, and O. S. Nielsen,
“Progression-free rate as the principal end-point for phase II
trials in soft-tissue sarcomas,” European Journal of Cancer, vol.
38, no. 4, pp. 543–549, 2002.
[19] N. Penel, M. Van Glabbeke, S. Marreaud, M. Ouali, J. Y. Blay,
and P. Hohenberger, “Testing new regimens in patients with
advanced soft tissue sarcoma: analysis of publications from the
last 10 years,” Annals of Oncology, vol. 22, no. 6, pp. 1266–1272,
2011.
[20] O. S. Nielsen, P. Dombernowsky, H. Mouridsen et al., “Epiru-
bicin is not superior to doxorubicin in the treatment of
advanced soft tissue sarcomas. The experience of the EORTC
soft tissue and bone sarcoma group,” Sarcoma, vol. 4, no. 1-2,
pp. 31–35, 2000.
[21] I. Judson, J. A. Radford, M. Harris et al., “Randomised phase II
trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®)
versus doxorubicin in the treatment of advanced or metastatic
soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone
Sarcoma Group,” European Journal of Cancer, vol. 37, no. 7, pp.
870–877, 2001.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
